ClinicalTrials.gg
CompletedNCT00770809Updated Aug 12, 2026Results posted

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

A Phase 3 interventional study of Laboratory Biomarker Analysis and Lapatinib Ditosylate in Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7 and Stage IIB Breast Cancer AJCC v6 and v7, sponsored by National Cancer Institute (NCI). Completed at 318 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by National Cancer Institute (NCI) · Phase 3, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies testing trastuzumab in Breast Neoplasms, Male — none open to participants now, 1 under way, none of them phase 3. Trastuzumab · Breast Neoplasms, Male.

Enrollment
Largest of 14
305 · median 51
Started
2009
with 2 others
Phase 3
Only one
of the 14
Registered
12th of 14
by date
Lead sponsor
3 of 14
National Cancer Institute (NCI)

Among the 14 studies testing trastuzumab in Breast Neoplasms, Male, this one has the largest enrollment, is one of 3 that started in 2009, is the only one in phase 3, and was the 12th registered.

Breast Neoplasms, Male

286 studies on the registry are indexed under Breast Neoplasms, Male; 5 are open to participants now.

Browse Breast Neoplasms, Male studies →

Open to participants now

None of the 14 studies testing trastuzumab in Breast Neoplasms, Male is open now. The open studies under Breast Neoplasms, Male, anywhere →

Where they have run

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Breast Neoplasms, Male studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing trastuzumab in Breast Neoplasms, Male as a file.
02

Study summary

This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel with trastuzumab and/or lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which regimen is more effective in treating patients with breast cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine if the pathologic complete response (pCR) in the breast to neoadjuvant weekly paclitaxel with trastuzumab plus lapatinib (THL) is 20% greater than the pCR to weekly paclitaxel with trastuzumab alone (TH).

SECONDARY OBJECTIVES:

I. To determine the pathologic complete response in the breast and axilla, using American Joint Committee on Cancer (AJCC) Tumor, Lymph Nodes and Metastasis (TMN) criteria (version 6), to neoadjuvant weekly paclitaxel plus human epidermal growth factor 2 (HER2)- targeted therapy in patients with HER2-positive operable breast cancer.

II. To evaluate residual cancer burden (RCB) as a predictor of long term relapse free survival (RFS) and overall survival (OS).

III. To document the toxicity of all chemotherapeutic regimens (THL, TH). IV. To determine the correlation between clinical, radiographic and pathologic response.

V. To compare overall survival (OS), relapse free survival (RFS) and time to first failure (TFF) among the treatment groups.

VI. To obtain blood, fresh frozen and fixed tumor tissue to test specific hypotheses for which biomarker data exist and to evaluate biomarkers in blood, serum and tissue that are likely to influence response to and toxicity of trastuzumab alone or trastuzumab plus lapatinib, when given with paclitaxel.

VII. To determine the surgical practice patterns for breast conservation and sentinel lymphadenectomy in patients undergoing neoadjuvant chemotherapy.

VIII. To determine the radiotherapy practice patterns for post-mastectomy and regional nodal irradiation in patients undergoing neoadjuvant chemotherapy.

IX. To evaluate pharmacogenomic determinants of toxicity.

OUTLINE: Patients are randomized to 1 of 3 treatment arms.

ARM I: Patients receive trastuzumab IV over 30-90 minutes and paclitaxel IV over 1 hour once weekly and lapatinib ditosylate orally (PO) once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive trastuzumab and paclitaxel as in arm I.

ARM III: Patients receive paclitaxel and lapatinib ditosylate as in arm I. (Discontinued as of 6-15-11) Within 42 days after completion of neoadjuvant therapy, patients in both arms undergo definitive surgery (breast conservation or total mastectomy).

After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 10 years.

03

Conditions studied

  • Male Breast Carcinoma
  • Stage IIA Breast Cancer AJCC v6 and v7
  • Stage IIB Breast Cancer AJCC v6 and v7
  • Stage IIIA Breast Cancer AJCC v7
  • Stage IIIB Breast Cancer AJCC v7
  • Stage IIIC Breast Cancer AJCC v7
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Pathologic confirmation of invasive breast cancer; patients with inflammatory breast cancer are not eligible
  • Clinical stage II-III operable invasive breast cancer with intent to perform surgical resection after therapy

    • Patients with multicentric or bilateral disease are eligible as long as the target lesion meets the eligibility criteria for this study
    • Staging to rule out disease is recommended for clinical stage III patients
  • Tumors must be positive defined as HER2 3+ by immunohistochemical (IHC) assays or gene amplification by fluorescence in situ hybridization (FISH) with a ratio of >= 2 on invasive tumor
  • Estrogen receptor (ER) and progesterone receptor (PgR) status must be known
  • The target lesion in the breast must be >= 1 cm on physical examination or by radiographic measurement; palpable axillary adenopathy will be documented but not serve as for the primary endpoint; patients with axillary disease only are not eligible to participate
  • Patient agrees to provide pretreatment
  • No prior chemotherapy, hormone therapy, biologic, or radiation therapy with therapeutic intent for this cancer
  • Cardiac must be >= 50% by echocardiogram or multiple gated acquisition (MUGA) scan
  • (ECOG) (Zubrod) performance status 0-1
  • Patients must not be pregnant or nursing
  • (ANC) >= 1,000/ul
  • count >= 100,000/ul
  • =\< 1.5 times
  • (AST) and alanine aminotransferase (ALT) =\< 2.5 times upper limit of normal (ULN)
  • Serum beta-human chorionic gonadotropin (HCG) negative (in female patients unless status-post (s/p) hysterectomy or menopausal or no menses for 24 consecutive months); assay must have a sensitivity of at least 50 mIU/mL
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    Arm I (THL)

    Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m\^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.

    Other: Laboratory Biomarker Analysis · Drug: Lapatinib Ditosylate · Drug: Paclitaxel · Biological: Trastuzumab

  • Active comparator
    Arm II (TH)

    Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m\^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity.

    Other: Laboratory Biomarker Analysis · Drug: Paclitaxel · Biological: Trastuzumab

  • Experimental
    Arm III (TL)

    Patients receive paclitaxel 80 mg/m\^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)

    Drug: Lapatinib Ditosylate · Drug: Paclitaxel

Interventions

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • DrugLapatinibStudies of LapatinibLapatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: Tykerb

  • Given IV

    Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat

  • BiologicalTrastuzumab

    Given IV

    Also known as: ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, HLX 02, HLX-02, HLX02, Kanjinti, Ogivri, Ontruzant, PF 05280014, PF-05280014, PF05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac

06

What researchers measure

Primary outcomes

  1. pCR Rate

    Complete pathological response is defined as the absence of residual invasive carcinoma in the breast at the time of definitive surgical removal. Pathologic complete response in the lymph nodes is defined as no detectable invasive tumor by H\&E. Analysis will use a chi-square test for the difference in proportions of patients on the THL arm versus the TH arm who achieve a pCR. Exact binomial methods will be used to construct 95% confidence intervals around the pCR incidence for each arm.

    Time frame: At time of surgery

Secondary outcomes

  1. Pathologic Stage in the Breast and Axilla

    Stage will be determined by the American Joint Committee on Cancer (AJCC) TNM (tumor, lymph nodes, metastasis) staging system. yT0: No evidence of residual invasive primary tumor. yTis: Carcinoma in situ only (presence of ductal carcinoma in situ \[DCIS\] but completely free of invasive cancer). yT1: Residual invasive tumor \<= 2 in greatest dimension.yT2: Residual invasive tumor \> 2 cm but \<= 5 cm in greatest dimension.yT3: Residual invasive tumor \> 5 cm in greatest dimension.yT4: Residual tumor of any size with direct extension to the chest wall and/or skin (including ulceration or macroscopic nodules).

    Time frame: At time of surgery

  2. Radiographic Response Rate (at Completion of Neoadjuvant Therapy)

    Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). A responding participant had either a complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions).

    Time frame: Week 16

  3. Overall Survival Rate

    Overall survival was measured as the interval from study entry until death, from any cause, or last contact. Distribution was estimated using the Kaplan Meier product-limit method

    Time frame: Time from randomization to death or last follow-up (up to 10 years)

  4. Relapse-free Survival (RFS) Rate

    Relapse free survival is defined as the interval from definitive surgery to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, or death from any cause, whichever occurs first. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Patients who do not undergo definitive surgery will not be assessable for RFS. Distribution was estimated using the Kaplan Meier product-limit method. Relapse-free survival (RFS) Rate is the rate of patients alive and relapse free.

    Time frame: Time from surgery to any recurrence (up to 10 years)

  5. Time to First Failure

    Time to first failure is defined as the interval from study entry to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence or death from any cause. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Distribution was estimated using the Kaplan Meier product-limit method.

    Time frame: Time from surgery to any recurrence (up to 10 years)

  6. Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3

    The type and grade of treatment-related toxicity will be tabulated by treatment arm.

    Time frame: Up to 30 days post-treatment

07

Results

Posted May 27, 2015

Participant flow

Participant flow — Overall Study
MilestoneArm I (THL)Arm II (TH)Arm III (TL)
Started11812067
Completed10111044
Not completed171023
Withdrew: Adverse event9112
Withdrew: Death100
Withdrew: Withdrawal by subject337
Withdrew: Progression220
Withdrew: Complicating illness001
Withdrew: Other medical reasons243

Outcome measures

PrimarypCR Rate

Complete pathological response is defined as the absence of residual invasive carcinoma in the breast at the time of definitive surgical removal. Pathologic complete response in the lymph nodes is defined as no detectable invasive tumor by H\&E. Analysis will use a chi-square test for the difference in proportions of patients on the THL arm versus the TH arm who achieve a pCR. Exact binomial methods will be used to construct 95% confidence intervals around the pCR incidence for each arm.

Time frame:
At time of surgery
Reported as:
Number · percentage of participants
pCR Rate
percentage of participantsArm I (THL)Arm II (TH)Arm III (TL)
pCR Rate56 (47 to 65)46 (35 to 55)32 (22 to 45)
Statistical analysis
  • Arm I (THL) vs Arm II (TH) · Log Rank · p = 0.13 (Participants were stratified by clinical stage (II vs III) and hormone receptor status (positive/negative).)
  • Arm II (TH) vs Arm III (TL) · Log Rank · p = 0.072 (Participants were stratified by clinical stage (II vs III) and hormone receptor status (positive/negative).)
SecondaryPathologic Stage in the Breast and Axilla

Stage will be determined by the American Joint Committee on Cancer (AJCC) TNM (tumor, lymph nodes, metastasis) staging system. yT0: No evidence of residual invasive primary tumor. yTis: Carcinoma in situ only (presence of ductal carcinoma in situ \[DCIS\] but completely free of invasive cancer). yT1: Residual invasive tumor \<= 2 in greatest dimension.yT2: Residual invasive tumor \> 2 cm but \<= 5 cm in greatest dimension.yT3: Residual invasive tumor \> 5 cm in greatest dimension.yT4: Residual tumor of any size with direct extension to the chest wall and/or skin (including ulceration or macroscopic nodules).

Time frame:
At time of surgery
Reported as:
Count of participants · Participants
Pathologic Stage in the Breast and Axilla
ParticipantsArm I (THL)Arm II (TH)Arm III (TL)
yT0504113
yT1374431
yT27128
yT3353
yT4020
yTi17137
Missing435
SecondaryRadiographic Response Rate (at Completion of Neoadjuvant Therapy)

Response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST). A responding participant had either a complete response (disappearance of all target lesions) or partial response (30% decrease in sum of longest diameter of target lesions).

Time frame:
Week 16
Reported as:
Count of participants · Participants
Radiographic Response Rate (at Completion of Neoadjuvant Therapy)
ParticipantsArm I (THL)Arm II (TH)Arm III (TL)
CR384820
PD121
PR384226
SD15113
Missing261717
SecondaryOverall Survival Rate

Overall survival was measured as the interval from study entry until death, from any cause, or last contact. Distribution was estimated using the Kaplan Meier product-limit method

Time frame:
Time from randomization to death or last follow-up (up to 10 years)
Reported as:
Number · proportion of participants
Overall Survival Rate
proportion of participantsArm I (THL)Arm II (TH)Arm III (TL)
Overall Survival Rate0.96 (0.92 to 0.99)0.87 (0.8 to 0.94)0.85 (0.76 to 0.95)
SecondaryRelapse-free Survival (RFS) Rate

Relapse free survival is defined as the interval from definitive surgery to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, or death from any cause, whichever occurs first. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Patients who do not undergo definitive surgery will not be assessable for RFS. Distribution was estimated using the Kaplan Meier product-limit method. Relapse-free survival (RFS) Rate is the rate of patients alive and relapse free.

Time frame:
Time from surgery to any recurrence (up to 10 years)
Reported as:
Number · proportion of participants
Relapse-free Survival (RFS) Rate
proportion of participantsArm I (THL)Arm II (TH)Arm III (TL)
Relapse-free Survival (RFS) Rate0.93 (0.88 to 0.98)0.77 (0.69 to 0.86)0.71 (0.60 to 0.84)
SecondaryTime to First Failure

Time to first failure is defined as the interval from study entry to ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence or death from any cause. Patients who have not experienced any of these events will be censored at the date of last clinical assessment. Distribution was estimated using the Kaplan Meier product-limit method.

Time frame:
Time from surgery to any recurrence (up to 10 years)
Reported as:
Number · proportion of participants
Time to First Failure
proportion of participantsArm I (THL)Arm II (TH)Arm III (TL)
Time to First Failure0.93 (0.88 to 0.98)0.79 (0.71 to 0.87)0.69 (0.58 to 0.82)
SecondaryIncidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3

The type and grade of treatment-related toxicity will be tabulated by treatment arm.

Time frame:
Up to 30 days post-treatment
Reported as:
Count of participants · Participants
Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3
ParticipantsArm I (THL)Arm II (TH)Arm III (TL)
Neutrophils828
Rash16210
Diarrhea25214
Febrile neutropenia001
Increased ALT613
Increased AST403
Sensory neuropathy1143
Thrombosis100
Hypokalemia701

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I (THL)—15/115 (13%)114/115 (99.1%)
Arm II (TH)—12/115 (10.4%)114/115 (99.1%)
Arm III (TL)—6/65 (9.2%)64/65 (98.5%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventArm I (THL)Arm II (TH)Arm III (TL)
DiarrheaGastrointestinal disorders12/1155/1155/65
FatigueGeneral disorders11/1158/1154/65
Hemoglobin decreasedBlood and lymphatic system disorders9/1157/1154/65
Rash desquamatingSkin and subcutaneous tissue disorders5/1152/1154/65
NauseaGastrointestinal disorders7/1152/1152/65
Peripheral sensory neuropathyNervous system disorders6/1154/1151/65
Alanine aminotransferase increasedInvestigations1/1152/1153/65
Neutrophil count decreasedInvestigations5/1153/1152/65
Aspartate aminotransferase increasedInvestigations2/1151/1152/65
VomitingGastrointestinal disorders3/1151/1151/65
Most frequent other events
Showing 10 of 131
Most frequent other events
EventArm I (THL)Arm II (TH)Arm III (TL)
FatigueGeneral disorders101/11597/11547/65
DiarrheaGastrointestinal disorders100/11555/11556/65
Peripheral sensory neuropathyNervous system disorders92/11584/11544/65
Rash desquamatingSkin and subcutaneous tissue disorders83/11549/11548/65
Hemoglobin decreasedBlood and lymphatic system disorders74/11572/11540/65
NauseaGastrointestinal disorders61/11545/11532/65
Neutrophil count decreasedInvestigations41/11529/11519/65
MyalgiaMusculoskeletal and connective tissue disorders28/11534/11522/65
VomitingGastrointestinal disorders18/11513/11516/65
Alanine aminotransferase increasedInvestigations15/1159/1156/65

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm I (THL)Arm II (TH)Arm III (TL)Total
Median48.5 (24.7 to 70.8)50.3 (30.2 to 75.8)48.3 (25.8 to 74.3)49.4 (24.7 to 75.8)
Sex: Female, Male
Sex: Female, Male(Participants)Arm I (THL)Arm II (TH)Arm III (TL)Total
Female11711967303
Male1102
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I (THL)Arm II (TH)Arm III (TL)Total
American Indian or Alaska Native1102
Asian48517
Native Hawaiian or Other Pacific Islander0101
Black or African American128727
White959751243
More than one race2002
Unknown or Not Reported45413
Region of Enrollment
Region of Enrollment(participants)Arm I (THL)Arm II (TH)Arm III (TL)Total
United States11812067305
Clinical Stage
Clinical Stage(participants)Arm I (THL)Arm II (TH)Arm III (TL)Total
Stage II818048209
Stage III37401996
Hormone Receptor Status
Hormone Receptor Status(participants)Arm I (THL)Arm II (TH)Arm III (TL)Total
ER/PgR Positive707039179
ER/PgR or Negative485028126
08

Study locations

318 sites
  • Banner University Medical Center - Tucson
    Tucson, Arizona 85719, United States
  • Sparks Regional Medical Center
    Fort Smith, Arkansas 72901, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center
    Burbank, California 91505, United States
  • East Bay Radiation Oncology Center
    Castro Valley, California 94546, United States
  • Eden Hospital Medical Center
    Castro Valley, California 94546, United States
  • Valley Medical Oncology Consultants-Castro Valley
    Castro Valley, California 94546, United States
  • Bay Area Breast Surgeons Inc
    Emeryville, California 94608, United States
  • Valley Medical Oncology Consultants-Fremont
    Fremont, California 94538, United States
  • Contra Costa Regional Medical Center
    Martinez, California 94553-3156, United States
  • El Camino Hospital
    Mountain View, California 94040, United States
  • Palo Alto Medical Foundation-Camino Division
    Mountain View, California 94040, United States
  • Wilma Chan Highland Hospital
    Oakland, California 94602, United States
  • Alta Bates Summit Medical Center - Summit Campus
    Oakland, California 94609, United States
  • Bay Area Tumor Institute
    Oakland, California 94609, United States
  • Hematology and Oncology Associates-Oakland
    Oakland, California 94609, United States
  • Tom K Lee Inc
    Oakland, California 94609, United States
  • Desert Regional Medical Center
    Palm Springs, California 92262, United States
  • Palo Alto Medical Foundation Health Care
    Palo Alto, California 94301, United States
  • Valley Care Health System - Pleasanton
    Pleasanton, California 94588, United States
  • Valley Medical Oncology Consultants
    Pleasanton, California 94588, United States
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Salinas Valley Memorial
    Salinas, California 93901, United States
  • Zuckerberg San Francisco General Hospital
    San Francisco, California 94110, United States
  • UCSF Medical Center-Mount Zion
    San Francisco, California 94115, United States
  • Doctors Medical Center- JC Robinson Regional Cancer Center
    San Pablo, California 94806, United States
  • Saint Helena Hospital
    St. Helena, California 94574, United States
  • The Medical Center of Aurora
    Aurora, Colorado 80012, United States
  • Boulder Community Foothills Hospital
    Boulder, Colorado 80303, United States
  • Penrose-Saint Francis Healthcare
    Colorado Springs, Colorado 80907, United States
  • AdventHealth Porter
    Denver, Colorado 80210, United States
  • Presbyterian - Saint Lukes Medical Center - Health One
    Denver, Colorado 80218, United States
  • Saint Joseph Hospital - Cancer Centers of Colorado
    Denver, Colorado 80218, United States
  • Rose Medical Center
    Denver, Colorado 80220, United States
  • Western States Cancer Research NCORP
    Denver, Colorado 80222, United States
  • Swedish Medical Center
    Englewood, Colorado 80113, United States
  • Saint Mary's Hospital and Regional Medical Center
    Grand Junction, Colorado 81501, United States
  • Banner North Colorado Medical Center
    Greeley, Colorado 80631, United States
  • Saint Anthony Hospital
    Lakewood, Colorado 80228, United States
  • AdventHealth Littleton
    Littleton, Colorado 80122, United States
  • Sky Ridge Medical Center
    Lone Tree, Colorado 80124, United States
  • Longmont United Hospital
    Longmont, Colorado 80501, United States
  • Banner McKee Medical Center
    Loveland, Colorado 80539, United States
  • AdventHealth Parker
    Parker, Colorado 80138, United States
  • Saint Mary Corwin Medical Center
    Pueblo, Colorado 81004, United States
  • North Suburban Medical Center
    Thornton, Colorado 80229, United States
  • Intermountain Health Lutheran Hospital
    Wheat Ridge, Colorado 80401, United States
  • Smilow Cancer Hospital Care Center at Saint Francis
    Hartford, Connecticut 06105, United States
  • Manchester Memorial Hospital
    Manchester, Connecticut 06040, United States
  • Middlesex Hospital
    Middletown, Connecticut 06457, United States
  • Beebe Medical Center
    Lewes, Delaware 19958, United States
  • Christiana Care Health System-Christiana Hospital
    Newark, Delaware 19718, United States
  • MedStar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
  • Halifax Health Medical Center-Centers for Oncology
    Daytona Beach, Florida 32114, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • Florida Cancer Specialists-Gainesville Cancer Center
    Gainesville, Florida 32605, United States
  • Jupiter Medical Center
    Jupiter, Florida 33458, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Cleveland Clinic-Weston
    Weston, Florida 33331, United States
  • Piedmont Hospital
    Atlanta, Georgia 30309, United States
  • Atlanta Regional CCOP
    Atlanta, Georgia 30342, United States
  • Emory Saint Joseph's Hospital
    Atlanta, Georgia 30342, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • WellStar Cobb Hospital
    Austell, Georgia 30106, United States
  • John B Amos Cancer Center
    Columbus, Georgia 31904, United States
  • Emory Decatur Hospital
    Decatur, Georgia 30033, United States
  • Piedmont Fayette Hospital
    Fayetteville, Georgia 30214, United States
  • Northside Hospital - Gwinnett
    Lawrenceville, Georgia 30046, United States
  • Atrium Health Navicent
    Macon, Georgia 31201, United States
  • Wellstar Kennestone Hospital
    Marietta, Georgia 30060, United States
  • Southern Regional Medical Center
    Riverdale, Georgia 30274, United States
  • Harbin Clinic Medical Oncology and Clinical Research
    Rome, Georgia 30165, United States
  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    Savannah, Georgia 31405, United States
  • Saint Alphonsus Cancer Care Center-Boise
    Boise, Idaho 83706, United States
  • OSF Saint Anthony's Health Center
    Alton, Illinois 62002, United States
  • Mount Sinai Hospital Medical Center
    Chicago, Illinois 60608, United States
  • University of Illinois
    Chicago, Illinois 60612, United States
  • Presence Resurrection Medical Center
    Chicago, Illinois 60631, United States
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
  • Weiss Memorial Hospital
    Chicago, Illinois 60640, United States
  • Advocate Good Samaritan Hospital
    Downers Grove, Illinois 60515, United States
  • Duly Health and Care Joliet
    Joliet, Illinois 60435, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • SSM Health Good Samaritan
    Mount Vernon, Illinois 62864, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453-2699, United States
  • Swedish American Hospital
    Rockford, Illinois 61104, United States
  • Franciscan Saint Francis Health-Beech Grove
    Beech Grove, Indiana 46107, United States
  • Fort Wayne Medical Oncology and Hematology Inc-Parkview
    Fort Wayne, Indiana 46845, United States
  • Reid Health
    Richmond, Indiana 47374, United States
  • McFarland Clinic - Ames
    Ames, Iowa 50010, United States
  • University of Iowa Healthcare Cancer Services Quad Cities
    Bettendorf, Iowa 52722, United States
  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
    Clive, Iowa 50325, United States
  • Mercy Capitol
    Des Moines, Iowa 50307, United States
  • Iowa Methodist Medical Center
    Des Moines, Iowa 50309, United States
  • Iowa-Wide Oncology Research Coalition NCORP
    Des Moines, Iowa 50309, United States
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic
    Des Moines, Iowa 50309, United States
  • Mercy Medical Center - Des Moines
    Des Moines, Iowa 50314, United States
  • UI Health Care Mission Cancer and Blood - Laurel Clinic
    Des Moines, Iowa 50314, United States
  • Iowa Lutheran Hospital
    Des Moines, Iowa 50316, United States
  • University of Iowa/Holden Comprehensive Cancer Center
    Iowa City, Iowa 52242, United States
  • Siouxland Regional Cancer Center
    Sioux City, Iowa 51101, United States

Showing the first 100 of 318 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jaehnig EJ, Fernandez-Martinez A, Vashist TD, Holt MV, Williams L, Lei JT, Moon CI, Kim BJ, Dou Y, Zhao H, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Perou CM, Carey LA, Robles AI, Hyslop T, Wen Y, McCart L, Krek A, Petralia F, Miles G, Kavuri SM, Gillette MA, Mani DR, Carr SA, Zhang B, Ellis MJ, Satpathy S, Anurag M. Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell Rep Med. 2025 Jun 17;6(6):102154. doi: 10.1016/j.xcrm.2025.102154. Epub 2025 Jun 5. PubMed 40480221 ↗
  • Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 Dec 10;38(35):4184-4193. doi: 10.1200/JCO.20.01276. Epub 2020 Oct 23. PubMed 33095682 ↗
  • Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. PubMed 26527775 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2009 to primary completion in Jan 2014, 59 months.

Results were first posted in May 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2008
First posted
Oct 10, 2008
StartActual
Feb 24, 2009
Primary completionActual
Jan 31, 2014
CompletionActual
Feb 15, 2024
Results first posted
May 27, 2015
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00770809
Responsible party
Sponsor
First posted
Oct 10, 2008
Start date
Feb 24, 2009
Primary completion
Jan 31, 2014
Completion
Feb 15, 2024
Results posted
May 27, 2015
Last update
Aug 12, 2026

Study contacts

Lisa A Carey
principal investigator · Alliance for Clinical Trials in Oncology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion